CYTOSORBENTS CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.33% for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-07.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2017-08-07
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 1.25%, a 45.35% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 0.86%, a 23.21% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.12%, a 35.26% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-03-31 was 1.73%.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2016 was 0.36%, a 73.33% decline from fiscal 2015.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2015 was 1.35%, a 5.59% decline from fiscal 2014.
- CYTOSORBENTS CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2014 was 1.43%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2017-06-30 | 1.33% 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | 1.25% 10-Q · filed 2017-05-08 | ||||
| 2016-12-31 | 0.36% 10-K · filed 2017-03-03 | ||||
| 2016-09-30 | 0.82% 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | 0.67% 10-Q · filed 2017-08-07 | ||||
| 2016-03-31 | 0.86% 10-Q · filed 2017-05-08 | ||||
| 2015-12-31 | 1.35% 10-K · filed 2017-03-03 | ||||
| 2015-09-30 | 1.02% 10-Q · filed 2016-11-07 | ||||
| 2015-06-30 | 1.23% 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | 1.12% 10-Q · filed 2016-05-09 | ||||
| 2014-12-31 | 1.43% 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | 1.60% 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | 1.62% 10-Q · filed 2014-08-12 | ||||
| 2014-03-31 | 1.73% 10-Q · filed 2014-05-14 | ||||
| 2014-03-11 | 1.62% 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |